Sicart Associates LLC lowered its position in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 24.8% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 248,199 shares of the medical instruments supplier’s stock after selling 82,050 shares during the quarter. OraSure Technologies accounts for 4.0% of Sicart Associates LLC’s investment portfolio, making the stock its 4th largest holding. Sicart Associates LLC owned 0.42% of OraSure Technologies worth $5,584,000 at the end of the most recent reporting period.
Other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. raised its holdings in OraSure Technologies by 127,593.4% in the first quarter. BlackRock Inc. now owns 7,743,325 shares of the medical instruments supplier’s stock valued at $100,123,000 after buying an additional 7,737,261 shares during the period. Daruma Capital Management LLC boosted its holdings in shares of OraSure Technologies by 2,761.0% during the second quarter. Daruma Capital Management LLC now owns 2,821,506 shares of the medical instruments supplier’s stock valued at $48,699,000 after acquiring an additional 2,722,886 shares during the period. Vanguard Group Inc. raised its stake in shares of OraSure Technologies by 30.3% during the first quarter. Vanguard Group Inc. now owns 4,466,499 shares of the medical instruments supplier’s stock valued at $57,752,000 after purchasing an additional 1,037,439 shares in the last quarter. Acadian Asset Management LLC raised its stake in shares of OraSure Technologies by 32.5% during the second quarter. Acadian Asset Management LLC now owns 1,846,854 shares of the medical instruments supplier’s stock valued at $31,877,000 after purchasing an additional 452,642 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. raised its stake in shares of OraSure Technologies by 2,181.8% during the third quarter. Robeco Institutional Asset Management B.V. now owns 434,550 shares of the medical instruments supplier’s stock valued at $9,778,000 after purchasing an additional 415,506 shares in the last quarter. Institutional investors own 94.41% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2017/11/23/sicart-associates-llc-sells-82050-shares-of-orasure-technologies-inc-osur.html.
In other OraSure Technologies news, Director Mara G. Aspinall purchased 5,000 shares of the firm’s stock in a transaction dated Tuesday, November 7th. The shares were bought at an average price of $14.23 per share, for a total transaction of $71,150.00. Following the purchase, the director now owns 5,000 shares in the company, valued at approximately $71,150. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Douglas A. Michels sold 25,000 shares of the business’s stock in a transaction on Friday, September 29th. The stock was sold at an average price of $22.55, for a total value of $563,750.00. Following the sale, the chief executive officer now owns 743,058 shares in the company, valued at approximately $16,755,957.90. The disclosure for this sale can be found here. Over the last three months, insiders have sold 58,035 shares of company stock valued at $1,297,612. 6.40% of the stock is currently owned by insiders.
OraSure Technologies, Inc. (NASDAQ OSUR) traded up $0.31 during midday trading on Thursday, hitting $16.86. The stock had a trading volume of 3,361,400 shares, compared to its average volume of 898,863. The firm has a market capitalization of $1,003.73, a price-to-earnings ratio of 31.83, a P/E/G ratio of 3.18 and a beta of 1.39. OraSure Technologies, Inc. has a 52 week low of $8.21 and a 52 week high of $23.01.
OraSure Technologies (NASDAQ:OSUR) last posted its quarterly earnings data on Wednesday, November 1st. The medical instruments supplier reported $0.09 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.09. The business had revenue of $42.30 million during the quarter, compared to the consensus estimate of $40.87 million. OraSure Technologies had a return on equity of 14.12% and a net margin of 20.48%. OraSure Technologies’s quarterly revenue was up 31.0% on a year-over-year basis. During the same period last year, the company earned $0.11 earnings per share. sell-side analysts expect that OraSure Technologies, Inc. will post 0.42 EPS for the current fiscal year.
A number of equities analysts recently weighed in on the company. Canaccord Genuity lifted their price target on OraSure Technologies from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Thursday, August 3rd. Zacks Investment Research raised OraSure Technologies from a “hold” rating to a “buy” rating and set a $23.00 price target for the company in a research note on Wednesday, October 25th. ValuEngine lowered OraSure Technologies from a “buy” rating to a “hold” rating in a report on Thursday, November 2nd. BidaskClub lowered OraSure Technologies from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $20.00 price target on shares of OraSure Technologies in a research report on Tuesday, September 12th. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. OraSure Technologies has a consensus rating of “Buy” and a consensus price target of $18.21.
OraSure Technologies Profile
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.